Is the risk of the glitazones worth the benefit? What if you could predict which patients were susceptible? Dr. Ruaño discusses with host Dr. Leslie Lundt how diabetes patients may benefit from the rapidly growing field of physiogenomics.
Is the risk of the glitazones worth the benefit? What if you could predict which patients were susceptible? Dr. Ruaño discusses with host Dr. Leslie Lundt how diabetes patients may benefit from the rapidly growing field of physiogenomics.
